SC
XENE icon

Scotia Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Scotia Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,859
Closed -$1.06M – 829
2022
Q4 		$1.06M Sell
26,859
-7,392
-22% -$269K 0.01% 442
2022
Q3 		$1.24M Sell
34,251
-3,223
-9% -$116K 0.01% 415
2022
Q2 		$1.14M Buy
37,474
+3,258
+10% +$98.5K 0.01% 453
2022
Q1 		$1.05M Buy
34,216
+520
+2% +$15.6K 0.01% 503
2021
Q4 		$1.05M Sell
33,696
-3,440
-9% -$103K 0.01% 514
2021
Q3 		$567K Sell
37,136
-2,881
-7% -$50.1K ﹤0.01% 609
2021
Q2 		$745K Sell
40,017
-1,120
-3% -$20.6K 0.01% 569
2021
Q1 		$736K Buy
41,137
+240
+0.6% +$4.07K 0.01% 545
2020
Q4 		$629K Sell
40,897
-837
-2% -$9.79K 0.01% 526
2020
Q3 		$462K Buy
41,734
+167
+0.4% +$1.97K 0.01% 518
2020
Q2 		$522K Buy
41,567
+21
+0.1% +$267 0.01% 420
2020
Q1 		$471K Sell
41,546
-20,963
-34% -$299K 0.01% 442
2019
Q4 		$820K Sell
62,509
-3,799
-6% -$40K 0.01% 423
2019
Q3 		$597K Sell
66,308
-629
-0.9% -$5.95K 0.01% 482
2019
Q2 		$660K Sell
66,937
-145
-0.2% -$1.39K 0.01% 473
2019
Q1 		$682K Buy
67,082
+378
+0.6% +$3.2K 0.01% 445
2018
Q4 		$421K Buy
66,704
+9,618
+17% +$85.5K 0.01% 484
2018
Q3 		$754K Sell
57,086
-7,271
-11% -$84.3K 0.01% 459
2018
Q2 		$314K Hold
64,357
– – ﹤0.01% 574
2018
Q1 		$315K Buy
64,357
+1,439
+2% +$5.32K ﹤0.01% 597
2017
Q4 		$178K Buy
62,918
+8,547
+16% +$23.2K ﹤0.01% 673
2017
Q3 		$160K Buy
54,371
+18,742
+53% +$58K ﹤0.01% 662
2017
Q2 		$112K Buy
35,629
+9,426
+36% +$36.8K ﹤0.01% 653
2017
Q1 		$105K Buy
26,203
+5,385
+26% +$42.3K ﹤0.01% 702
2016
Q4 		$160K Sell
20,818
-2
-0% -$16 ﹤0.01% 754
2016
Q3 		$169K Buy
+20,820
New +$161K ﹤0.01% 734

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Scotia Capital's XENE Position: Q1 2023 in Review

Scotia Capital sold out of Xenon Pharmaceuticals (XENE) in Q1 2023, closing a stake of 26,859 shares — an estimated $1.06M sold.

Scotia Capital first reported a position in XENE in Q3 2016 and held it in 26 quarters. The position peaked at $1.24M in Q3 2022. 163 funds tracked by Wall St. Rank hold XENE as of Q1 2023.

  • Scotia Capital reported no remaining Xenon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Scotia Capital sold 26,859 Xenon Pharmaceuticals shares in Q1 2023, an estimated $1.06M.
  • Scotia Capital first reported a position in Xenon Pharmaceuticals in Q3 2016 and held it in 26 quarters.
  • Scotia Capital's Xenon Pharmaceuticals position peaked at $1.24M in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2023.

Based on Scotia Capital's 13F filing for Q1 2023, filed 11 May 2023.